Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2003

01-06-2003 | Observation

Multiple autoantibodies as predictors of Type 1 diabetes in a general population

Authors: N. K. Maclaren, M. S. Lan, D. Schatz, J. Malone, Dr. A. L. Notkins, J. Krischer

Published in: Diabetologia | Issue 6/2003

Login to get access

Excerpt

To the Editor: Autoantibodies have been widely used to predict the development of Type 1 diabetes [1]. Most studies have been carried out on first-degree relatives of Type 1 diabetic patients [2, 3, 4] who are at a 10 to 15-fold higher risk of developing the disease than people in the general population. However, approximately 85% of all patients who develop Type 1 diabetes do not have an affected family member. …
Literature
1.
Notkins AL, Lernmark A (2001) Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108:1247–1252CrossRefPubMed
2.
Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46:1701–1710PubMed
3.
Kulmala P, Savola K, Peterson JS et al. (1998) Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 101:323–336
4.
Maclaren N, Lan M, Coutant R et al. (1999) Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (type 1) diabetes in relatives. J Autoimmun 12:279–287PubMed
5.
Samuelsson U, Sundkvist G, Borg H, Fernlund P, Ludvigsson J (2001) Islet autoantibodies in the prediction of diabetes in school children. Diabetes Res Clin Pract 51:51–57CrossRefPubMed
6.
LaGasse JM, Brantley MS, Leech NJ et al. (2002) Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 25:505–511PubMed
7.
Kimpimaki T, Kulmala P, Savola K et al. (2002) Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 87:4572–4579CrossRefPubMed
8.
Schlosser M, Strebelow M, Wassmuth R et al. (2002) The Karlsburg type 1 diabetes risk study of a normal schoolchild population: association of beta-cell autoantibodies and human leukocyte antigen-DQB1 alleles in antibody-positive individuals. J Clin Endocrinol Metab 87:2254–2261PubMed
Metadata
Title
Multiple autoantibodies as predictors of Type 1 diabetes in a general population
Authors
N. K. Maclaren
M. S. Lan
D. Schatz
J. Malone
Dr. A. L. Notkins
J. Krischer
Publication date
01-06-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1123-7

Other articles of this Issue 6/2003

Diabetologia 6/2003 Go to the issue

Comment

Distribution of HERV-LTR elements in HLA-DQB1 alleles: comments on the article by Bieda et al.

Article

Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes

Short Communication

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Observation

Compensatory hypochloraemic alkalosis in diabetic ketoacidosis

Article

Ectopic expression of the beta-cell specific transcription factor Pdx1 inhibits glucagon gene transcription

Article

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits